Bio-Rad Laboratories (BUWA) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BUWA Analyst Ratings

Moderate Buy

1 Buy

2 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Bio-Rad

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BUWA Stock 12 Month Forecast

Average Price Target

€300.23

▲(5.27% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Bio-Rad Laboratories in the last 3 months. The average price target is €300.23 with a high forecast of €334.55 and a low forecast of €283.08. The average price target represents a 5.27% change from the last price of €285.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"227":"€227","254":"€254","281":"€281","308":"€308","335":"€335"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":334.545705,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€334.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300.233325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€300.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":283.077135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€283.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[227,254,281,308,335],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,282,286.0419773076923,290.08395461538464,294.1259319230769,298.1679092307692,302.20988653846155,306.25186384615387,310.29384115384613,314.33581846153845,318.3777957692308,322.4197730769231,326.46175038461536,330.5037276923077,{"y":334.545705,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,282,283.4025634615385,284.8051269230769,286.2076903846154,287.61025384615385,289.0128173076923,290.41538076923075,291.8179442307692,293.2205076923077,294.6230711538461,296.0256346153846,297.4281980769231,298.8307615384615,{"y":300.233325,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,282,282.08285653846156,282.16571307692305,282.2485696153846,282.33142615384617,282.41428269230767,282.4971392307692,282.5799957692308,282.66285230769233,282.74570884615383,282.8285653846154,282.91142192307694,282.99427846153844,{"y":283.077135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":228,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.8,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":251.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":261.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":282,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€334.55

Average Price Target€300.23

Lowest Price Target€283.08

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dan Leonard

RBC Capital

€317.39→€334.55

Buy

17.30%

Upside

Reiterated

08/06/26

Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)

Brandon Couillard

Wells Fargo

€265.92→€283.08

Hold

-0.74%

Downside

Assigned

08/05/26

Wells Fargo Remains a Hold on Bio-Rad Laboratories (BIO)

Daniel Grosslight

Citi

€257.34→€283.08

Hold

-0.74%

Downside

Reiterated

08/05/26

Citi Reaffirms Their Hold Rating on Bio-Rad Laboratories (BIO)

Tycho Peterson

Jefferies

€235.9

Hold

-17.29%

Downside

Reiterated

05/21/26

Jefferies Keeps Their Hold Rating on Bio-Rad Laboratories (BIO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dan Leonard

RBC Capital

€317.39→€334.55

Buy

17.30%

Upside

Reiterated

08/06/26

Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)

Brandon Couillard

Wells Fargo

€265.92→€283.08

Hold

-0.74%

Downside

Assigned

08/05/26

Wells Fargo Remains a Hold on Bio-Rad Laboratories (BIO)

Daniel Grosslight

Citi

€257.34→€283.08

Hold

-0.74%

Downside

Reiterated

08/05/26

Citi Reaffirms Their Hold Rating on Bio-Rad Laboratories (BIO)

Tycho Peterson

Jefferies

€235.9

Hold

-17.29%

Downside

Reiterated

05/21/26

Jefferies Keeps Their Hold Rating on Bio-Rad Laboratories (BIO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bio-Rad Laboratories

3 Months

Dan LeonardRBC Capital

Success Rate

14/22 ratings generated profit

Average Return

+7.05%

Copying Dan Leonard's trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +7.05% per trade.

1 Year

Dan LeonardRBC Capital

Success Rate

11/22 ratings generated profit

Average Return

+7.05%

Copying Dan Leonard's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.05% per trade.

2 Years

Dan LeonardRBC Capital

Success Rate

12/22 ratings generated profit

Average Return

+6.09%

Copying Dan Leonard's trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +6.09% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BUWA Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BUWA has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. BUWA average Analyst price target in the past 3 months is 300.23.

Each month's total comprises the sum of three months' worth of ratings.

BUWA Financial Forecast

BUWA Earnings Forecast

Next quarter’s earnings estimate for BUWA is €1.93 with a range of €1.83 to €2.04. The previous quarter’s EPS was €2.27. BUWA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BUWA has Performed in-line its overall industry.

BUWA Sales Forecast

Next quarter’s sales forecast for BUWA is €563.00M with a range of €559.93M to €567.28M. The previous quarter’s sales results were €563.31M. BUWA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BUWA has Performed in-line its overall industry.

BUWA Stock Forecast FAQ

What is DE:BUWA’s average 12-month price target, according to analysts?

Based on analyst ratings, Bio-Rad Laboratories’s 12-month average price target is 300.23.

What is DE:BUWA’s upside potential, based on the analysts’ average price target?

Bio-Rad Laboratories has 5.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bio-Rad Laboratories a Buy, Sell or Hold?

Bio-Rad Laboratories has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.

What is Bio-Rad Laboratories’s share price target?

The average share price target for Bio-Rad Laboratories is 300.23. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €334.55 ,and the lowest forecast is €283.08. The average share price target represents 5.27% Increase from the current price of €285.2.

What do analysts say about Bio-Rad Laboratories?

Bio-Rad Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Bio-Rad Laboratories?

To buy shares of DE:BUWA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Bio-Rad Laboratories (BUWA) Stock Forecast & Price Target

BUWA Analyst Ratings

BUWA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bio-Rad Laboratories

BUWA Analyst Recommendation Trends

BUWA Financial Forecast

BUWA Earnings Forecast

BUWA Sales Forecast

BUWA Stock Forecast FAQ

Detailed List of Analyst Forecasts